[et_pb_section fb_built=”1″ _builder_version=”4.4.8″ use_background_color_gradient=”on” background_color_gradient_start=”rgba(0,151,202,0.69)” background_color_gradient_end=”rgba(0,85,147,0.8)” background_color_gradient_overlays_image=”on” background_image=”https://secureservercdn.net/198.71.233.106/d43.23a.myftpupload.com/wp-content/uploads/2017/10/bg.jpg” background_position=”top_center” custom_margin=”0px||||false|false” custom_padding=”0px||1%||false|false” bottom_divider_style=”curve” bottom_divider_color=”#ffffff” bottom_divider_height=”80px” bottom_divider_arrangement=”above_content” da_disable_devices=”off|off|off” global_module=”6694″ saved_tabs=”all” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.4.8″ max_width=”1080px” custom_margin=”0px||||false|false” custom_padding=”0px||10px||false|false”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_post_title meta=”off” featured_image=”off” text_color=”light” _builder_version=”4.4.8″ title_font=”|600|||||||” title_font_size=”56px” text_orientation=”center” custom_padding=”0px||||false|false” title_font_size_tablet=”36px” title_font_size_phone=”28px” title_font_size_last_edited=”on|phone”][/et_pb_post_title][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22″ da_disable_devices=”off|off|off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”3.25″ max_width=”960″ use_custom_width=”on” custom_width_px=”960″][et_pb_column type=”4_4″ _builder_version=”3.0.47″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.4.8″ header_5_font_size=”20px” hover_enabled=”0″ z_index_tablet=”500″ text_text_shadow_horizontal_length_tablet=”0px” text_text_shadow_vertical_length_tablet=”0px” text_text_shadow_blur_strength_tablet=”1px” link_text_shadow_horizontal_length_tablet=”0px” link_text_shadow_vertical_length_tablet=”0px” link_text_shadow_blur_strength_tablet=”1px” ul_text_shadow_horizontal_length_tablet=”0px” ul_text_shadow_vertical_length_tablet=”0px” ul_text_shadow_blur_strength_tablet=”1px” ol_text_shadow_horizontal_length_tablet=”0px” ol_text_shadow_vertical_length_tablet=”0px” ol_text_shadow_blur_strength_tablet=”1px” quote_text_shadow_horizontal_length_tablet=”0px” quote_text_shadow_vertical_length_tablet=”0px” quote_text_shadow_blur_strength_tablet=”1px” header_text_shadow_horizontal_length_tablet=”0px” header_text_shadow_vertical_length_tablet=”0px” header_text_shadow_blur_strength_tablet=”1px” header_2_text_shadow_horizontal_length_tablet=”0px” header_2_text_shadow_vertical_length_tablet=”0px” header_2_text_shadow_blur_strength_tablet=”1px” header_3_text_shadow_horizontal_length_tablet=”0px” header_3_text_shadow_vertical_length_tablet=”0px” header_3_text_shadow_blur_strength_tablet=”1px” header_4_text_shadow_horizontal_length_tablet=”0px” header_4_text_shadow_vertical_length_tablet=”0px” header_4_text_shadow_blur_strength_tablet=”1px” header_5_text_shadow_horizontal_length_tablet=”0px” header_5_text_shadow_vertical_length_tablet=”0px” header_5_text_shadow_blur_strength_tablet=”1px” header_6_text_shadow_horizontal_length_tablet=”0px” header_6_text_shadow_vertical_length_tablet=”0px” header_6_text_shadow_blur_strength_tablet=”1px” box_shadow_horizontal_tablet=”0px” box_shadow_vertical_tablet=”0px” box_shadow_blur_tablet=”40px” box_shadow_spread_tablet=”0px”]

— Five Thought-leading Experts in Oncology Drug Development Join Arch Oncology’s SAB —

BRISBANE, CA and ST. LOUIS, MO, June 22, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, announced today the formation of a Scientific Advisory Board (SAB) and appointment of five leading oncology experts. The SAB will work closely with Arch Oncology’s leadership as the Company advances its novel antibody therapeutics for solid tumors and hematologic malignancies.

“We are honored to have the opportunity to work with this distinguished group of immuno-oncology thought leaders who have pioneered numerous advances in our field,” said Dan Pereira, Ph.D., Chief Scientific Officer of Arch Oncology. “Their insights will inform our development plans to advance our lead therapy AO-176, a highly-differentiated, clinical-stage anti-CD47 antibody, in both solid tumors and multiple myeloma. Additionally, we look forward to leveraging their tremendous expertise as we continue to build our pipeline of novel immuno-oncology therapeutics. We are excited to welcome Drs. Cesano, Anderson, Harrington, Luke, and Pagel to our SAB.”

Arch Oncology’s SAB is comprised of:

Alessandra Cesano, M.D., Ph.D. – Chair
Dr. Cesano is Chief Medical Officer of ESSA Pharma Inc. Dr. Cesano is an accomplished drug development leader with extensive experience in drug discovery and development. She played key roles at Amgen in the approval of Vectibix® and Kepivance®. Previously, Dr. Cesano was the Chief Medical Officer at NanoString Technologies, Inc. Earlier, she served as the Chief Medical officer at Cleave Biosciences, Inc. and Chief Medical officer and Chief Operating Officer at Nodality, Inc. For over a decade, Dr. Cesano conducted research on tumor immunology, including nine years at the Wistar Institute of the University of Pennsylvania. She served as Co-chair in the SITC Industry Committee and currently is serving as Co-chair of the SITC Biomarker Committee and the SITC Cancer Immune Response Taskforce. She is also serving a three year term as At-large Director in the SITC Board of Directors (2020-2022). Dr. Cesano earned an M.D., a Board Certification in Oncology, and a Ph.D. in Tumor Immunology from the University of Turin.

Kenneth C. Anderson, M.D.
Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. Over the last four decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed models of the tumor in its microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, rapidly translating these studies to clinical trials culminating in FDA approval of novel targeted and immune therapies. He was elected to the Institute of Medicine and is a Fellow of both AACR Academy and ASCO. He is past President of ASH and of the International Myeloma Society. He earned an M.D. from Johns Hopkins Medical School, trained in internal medicine at Johns Hopkins Hospital, and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute.

Kevin Harrington, Ph.D., FRCP, FRCR
Dr. Harrington is Professor of Biological Cancer Therapies and Joint Head of the Division of Radiotherapy and Imaging at The Institute of Cancer Research in the UK. Dr. Harrington is also an Honorary Consultant Oncologist at the Royal Marsden and St George’s Hospital as well as a Fellow of the Royal College of Physicians and the Royal College of Radiologists. Dr. Harrington studies the use of biologically targeted agents, in combination with treatments such as radiotherapy and chemotherapy, to target cancer cells selectively. He is a specialist in head and neck cancer and in melanoma. Dr. Harrington received medical training from St Bartholomew’s Hospital and earned a Ph.D. from Hammersmith Hospital in London.

Jason Luke, M.D., FACP
Dr. Luke is an Associate Professor of Medicine in the Division of Hematology/Oncology at the University of Pittsburgh and the Director of the Cancer Immunotherapeutics Center within the UPMC Hillman Cancer Center. Dr. Luke has a clinical research focus on the development of novel immunotherapies for advanced solid tumors, and particularly melanoma. Dr. Luke is the Principal Investigator of the UPMC Hillman enterprise genomic sequencing platform and leads a translational bioinformatics group focused on application of large scale multi-omic data to inform immunotherapy resistance, biomarker development and novel treatment strategies. Dr. Luke has been the leader of the Melanoma Committee for the American Society of Clinical Oncology and has held leadership positions within the Society for Immunotherapy of Cancer. He earned an M.D. from Rosalind Franklin University of Medicine and Science and trained in medical oncology at Memorial Sloan-Kettering Cancer Center.

John M. Pagel M.D., Ph.D.
Dr. Pagel is Chief of Hematologic Malignancies and the Director of Stem Cell Transplantation at Swedish Cancer Institute in Seattle, Washington where he specializes in caring for patients with acute and chronic leukemias: Hodgkin and non-Hodgkin lymphomas, and myelodysplastic syndromes, as well as other myeloproliferative disorders. For over a decade, Dr. Pagel served as an Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center and Associate Professor, Medical Oncology Division, University of Washington. Dr. Pagel earned an M.D. from Boston University School of Medicine and a Ph.D. from the University of California, Irvine.

About Arch Oncology

Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with select solid tumors and hematologic malignancies, including multiple myeloma. The Company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. Arch Oncology’s lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, the Company is advancing a pipeline of antibody programs for the treatment of cancer. For more information please visit www.archoncology.com.

Media Contact:
Amy Figueroa
For Arch Oncology
afigueroa@archoncology.com

View all news

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.4.8″ background_color=”#0097ca” custom_margin=”0px||0px|” custom_padding=”0||0||true|false” top_divider_style=”curve2″ top_divider_color=”#ffffff” top_divider_flip=”vertical” da_disable_devices=”off|off|off” disabled=”on” global_module=”6648″ saved_tabs=”all” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”3.25″ background_color=”#0191ac” max_width=”1080px” custom_padding=”0|0px|0|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ background_color=”#0191ac” custom_padding=”|||” custom_padding__hover=”|||”][/et_pb_column][/et_pb_row][/et_pb_section]

October 27-29, 2020
Dr. Arun Kashyap will be speaking in Boston, MA, USA

November 4-5, 2020
Dr. Dan Pereira will be speaking in Boston, MA, USA

November 9-13, 2020
Dr. Dan Pereira will be speaking in Lisbon, Portugal

[et_pb_section fb_built=”1″ _builder_version=”4.4.8″ use_background_color_gradient=”on” background_color_gradient_start=”rgba(0,151,202,0.69)” background_color_gradient_end=”rgba(0,85,147,0.8)” background_color_gradient_overlays_image=”on” background_image=”https://secureservercdn.net/198.71.233.106/d43.23a.myftpupload.com/wp-content/uploads/2017/10/bg.jpg” background_position=”top_center” custom_margin=”0px||||false|false” custom_padding=”0px||1%||false|false” bottom_divider_style=”curve” bottom_divider_color=”#ffffff” bottom_divider_height=”80px” bottom_divider_arrangement=”above_content” global_module=”6694″ saved_tabs=”all” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on” da_disable_devices=”off|off|off”][et_pb_row _builder_version=”4.4.8″ max_width=”1080px” custom_margin=”0px||||false|false” custom_padding=”0px||10px||false|false”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_post_title meta=”off” featured_image=”off” text_color=”light” _builder_version=”4.4.8″ title_font=”|600|||||||” title_font_size=”56px” text_orientation=”center” custom_padding=”0px||||false|false”][/et_pb_post_title][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22″ da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on” da_disable_devices=”off|off|off”][et_pb_row _builder_version=”3.25″ max_width=”960″ use_custom_width=”on” custom_width_px=”960″][et_pb_column type=”4_4″ _builder_version=”3.0.47″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.4.8″ header_5_font_size=”20px” hover_enabled=”0″ z_index_tablet=”500″ text_text_shadow_horizontal_length_tablet=”0px” text_text_shadow_vertical_length_tablet=”0px” text_text_shadow_blur_strength_tablet=”1px” link_text_shadow_horizontal_length_tablet=”0px” link_text_shadow_vertical_length_tablet=”0px” link_text_shadow_blur_strength_tablet=”1px” ul_text_shadow_horizontal_length_tablet=”0px” ul_text_shadow_vertical_length_tablet=”0px” ul_text_shadow_blur_strength_tablet=”1px” ol_text_shadow_horizontal_length_tablet=”0px” ol_text_shadow_vertical_length_tablet=”0px” ol_text_shadow_blur_strength_tablet=”1px” quote_text_shadow_horizontal_length_tablet=”0px” quote_text_shadow_vertical_length_tablet=”0px” quote_text_shadow_blur_strength_tablet=”1px” header_text_shadow_horizontal_length_tablet=”0px” header_text_shadow_vertical_length_tablet=”0px” header_text_shadow_blur_strength_tablet=”1px” header_2_text_shadow_horizontal_length_tablet=”0px” header_2_text_shadow_vertical_length_tablet=”0px” header_2_text_shadow_blur_strength_tablet=”1px” header_3_text_shadow_horizontal_length_tablet=”0px” header_3_text_shadow_vertical_length_tablet=”0px” header_3_text_shadow_blur_strength_tablet=”1px” header_4_text_shadow_horizontal_length_tablet=”0px” header_4_text_shadow_vertical_length_tablet=”0px” header_4_text_shadow_blur_strength_tablet=”1px” header_5_text_shadow_horizontal_length_tablet=”0px” header_5_text_shadow_vertical_length_tablet=”0px” header_5_text_shadow_blur_strength_tablet=”1px” header_6_text_shadow_horizontal_length_tablet=”0px” header_6_text_shadow_vertical_length_tablet=”0px” header_6_text_shadow_blur_strength_tablet=”1px” box_shadow_horizontal_tablet=”0px” box_shadow_vertical_tablet=”0px” box_shadow_blur_tablet=”40px” box_shadow_spread_tablet=”0px”]

BRISBANE, CA and ST. LOUIS, MO, April 21, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Julie Hambleton, M.D. to the Company’s Board of Directors.

“Julie is an accomplished biotechnology executive who brings extensive oncology clinical drug development expertise to our Board of Directors,” said Julie M. Cherrington, Ph.D., President and Chief Executive Officer of Arch Oncology. “As we continue to advance AO-176 in clinical development for select solid tumors and plan for additional indications in hematologic malignancies including multiple myeloma, I am thrilled to have Julie join the Board of Directors. We share a deep commitment to developing novel therapies for patients with cancer and I look forward to working with her.”

Julie Hambleton, M.D., Chief Medical Officer at IDEAYA Biosciences and Director for Arch Oncology, added, “I am very encouraged by the growing body of preclinical data, the clinical progress, and future clinical potential of AO-176. This novel anti-CD47 antibody has a best-in-class profile and I look forward to sharing my insights gained over 20 years in drug development to guide ongoing and future potential opportunities for AO-176 in across various oncology indications.”

Julie Hambleton, M.D. is a senior biotechnology executive with over 20 years of experience in clinical drug development from pre-clinical through Phase 4 and post-marketing studies. She has extensive experience working with regulatory agencies, including the U.S. FDA and the European Medicines Agency (EMA), and in filings of Investigational New Drug Applications (INDs), Biologics License Applications (BLAs), and Special Protocol Assessments (SPAs). Dr. Hambleton serves as Chief Medical Officer of IDEAYA Biosciences. Previously, she was Vice President, Head of U.S. Medical at Bristol-Myers Squibb, overseeing Medical & Health Economic and Outcomes Research activities in support of the Oncology, Immuno-Oncology, Specialty and Cardiovascular marketed portfolios. Previously, she served as Executive Vice President and Chief Medical Officer at Five Prime Therapeutics and Vice President, Clinical Development, at Clovis Oncology. Dr. Hambleton began her industry career at Genentech, most recently as Group Medical Director, Global Clinical Development, leading a cross-functional group conducting Phase 2 and 3 trials of Avastin®.

Dr. Hambleton completed her medical and hematology-oncology training at the University California, San Francisco, where she then served on faculty from 1993 to 2003. She received a B.S. from Duke University, and M.D. from Case Western Reserve University School of Medicine and was Board-certified in Hematology and Internal Medicine.

In addition, Dr. Hambleton serves as a Director on IGM Biosciences’ Board of Directors.

About Arch Oncology

Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with select solid tumors and hematologic malignancies, including multiple myeloma. The Company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. Arch Oncology’s lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, the Company is advancing a number of antibody pipeline programs for the treatment cancer. For more information please visit www.archoncology.com.

Media Contact:
Amy Figueroa
For Arch Oncology
afigueroa@archoncology.com

View all news

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.4.8″ background_color=”#0097ca” custom_margin=”0px||0px|” custom_padding=”0||0||true|false” top_divider_style=”curve2″ top_divider_color=”#ffffff” top_divider_flip=”vertical” da_disable_devices=”off|off|off” disabled=”on” global_module=”6648″ saved_tabs=”all” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”3.25″ background_color=”#0191ac” max_width=”1080px” custom_padding=”0|0px|0|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ background_color=”#0191ac” custom_padding=”|||” custom_padding__hover=”|||”][/et_pb_column][/et_pb_row][/et_pb_section]

Publication: Molecular Cancer Therapeutics. Published first online on December 26, 2019.

Authors: Robyn J. Puro, Myriam N. Bouchlaka, Ronald R. Hiebsch, Benjamin J. Capoccia, Michael J. Donio, Pamela T. Manning, William A. Frazier, Robert W. Karr, and Daniel S. Pereira

 

Poster Presentation: Highly Differentiated Anti-CD47 Antibody AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination in Pre-Clinical Models

Poster Presentation: Novel SIRP Antibodies with Differentiated Characteristics for Targeting Innate Immunity in Cancer

Poster Presentation: AO-176, a highly differentiated humanized anti-CD47 antibody, exhibits single-agent and combination anti-tumor efficacy with chemotherapy and targeted antibodies in preclinical models (Abstract #: B100)

[et_pb_section fb_built=”1″ _builder_version=”4.4.8″ use_background_color_gradient=”on” background_color_gradient_start=”rgba(0,151,202,0.69)” background_color_gradient_end=”rgba(0,85,147,0.8)” background_color_gradient_overlays_image=”on” background_image=”https://secureservercdn.net/198.71.233.106/d43.23a.myftpupload.com/wp-content/uploads/2017/10/bg.jpg” background_position=”top_center” custom_margin=”0px||||false|false” custom_padding=”0px||1%||false|false” bottom_divider_style=”curve” bottom_divider_color=”#ffffff” bottom_divider_height=”80px” bottom_divider_arrangement=”above_content” global_module=”6694″ saved_tabs=”all” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on” da_disable_devices=”off|off|off”][et_pb_row _builder_version=”4.4.8″ max_width=”1080px” custom_margin=”0px||||false|false” custom_padding=”0px||10px||false|false”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_post_title meta=”off” featured_image=”off” text_color=”light” _builder_version=”4.4.8″ title_font=”|600|||||||” title_font_size=”56px” text_orientation=”center” custom_padding=”0px||||false|false”][/et_pb_post_title][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22″ da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on” da_disable_devices=”off|off|off”][et_pb_row _builder_version=”3.25″ max_width=”960″ use_custom_width=”on” custom_width_px=”960″][et_pb_column type=”4_4″ _builder_version=”3.0.47″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.4.8″ header_5_font_size=”20px” hover_enabled=”0″ z_index_tablet=”500″ text_text_shadow_horizontal_length_tablet=”0px” text_text_shadow_vertical_length_tablet=”0px” text_text_shadow_blur_strength_tablet=”1px” link_text_shadow_horizontal_length_tablet=”0px” link_text_shadow_vertical_length_tablet=”0px” link_text_shadow_blur_strength_tablet=”1px” ul_text_shadow_horizontal_length_tablet=”0px” ul_text_shadow_vertical_length_tablet=”0px” ul_text_shadow_blur_strength_tablet=”1px” ol_text_shadow_horizontal_length_tablet=”0px” ol_text_shadow_vertical_length_tablet=”0px” ol_text_shadow_blur_strength_tablet=”1px” quote_text_shadow_horizontal_length_tablet=”0px” quote_text_shadow_vertical_length_tablet=”0px” quote_text_shadow_blur_strength_tablet=”1px” header_text_shadow_horizontal_length_tablet=”0px” header_text_shadow_vertical_length_tablet=”0px” header_text_shadow_blur_strength_tablet=”1px” header_2_text_shadow_horizontal_length_tablet=”0px” header_2_text_shadow_vertical_length_tablet=”0px” header_2_text_shadow_blur_strength_tablet=”1px” header_3_text_shadow_horizontal_length_tablet=”0px” header_3_text_shadow_vertical_length_tablet=”0px” header_3_text_shadow_blur_strength_tablet=”1px” header_4_text_shadow_horizontal_length_tablet=”0px” header_4_text_shadow_vertical_length_tablet=”0px” header_4_text_shadow_blur_strength_tablet=”1px” header_5_text_shadow_horizontal_length_tablet=”0px” header_5_text_shadow_vertical_length_tablet=”0px” header_5_text_shadow_blur_strength_tablet=”1px” header_6_text_shadow_horizontal_length_tablet=”0px” header_6_text_shadow_vertical_length_tablet=”0px” header_6_text_shadow_blur_strength_tablet=”1px” box_shadow_horizontal_tablet=”0px” box_shadow_vertical_tablet=”0px” box_shadow_blur_tablet=”40px” box_shadow_spread_tablet=”0px”]

BRISBANE, CA and ST. LOUIS, MO, August 12, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Drew Dennison to the Company’s Board of Directors.

“Drew brings significant financial and operational experience to our Board of Directors as we work to advance our pipeline of novel antibody therapeutics,” said Julie M. Cherrington, Ph.D., President and Chief Executive Officer of Arch Oncology. “This is an important year for Arch Oncology, with additional preclinical data on AO-176 pointing to new clinical development opportunities and with our pipeline programs advancing. As we prepare for the future, we look forward to Drew’s contributions and welcome him to the Board of Directors.”

Drew Dennison, Managing Director at Lightchain Capital, LLC and Director for Arch Oncology, added, “Earlier this year, Lightchain led Arch Oncology’s Series B financing, based on our excitement about the leadership team that Julie assembled and the promise of the AO-176 clinical program. As AO-176 and the pipeline programs advance, I have become increasingly enthusiastic about the future of Arch Oncology. I look forward to working with the Board and senior leadership team at Arch Oncology, as the Company advances what we believe is a best-in-class antibody therapeutic in the anti-CD47 space.”

Drew Dennison is Managing Director at Lightchain Capital, LLC, the family office for Scottrade Founder and former Chief Executive Officer Rodger Riney. At Lightchain, Mr. Dennison is responsible for venture capital investments in the life science and technology sectors. He also assists the Riney Foundations with their philanthropic endeavors. Previously, Mr. Dennison served as the Chief Operating Officer and Chief Financial Officer at Scottrade Financial Services, Inc. He led the Company’s operations, technology, operations, finance, and strategic planning functions and worked at the Company for over a decade. Mr. Dennison led the sale of Scottrade to TD Ameritrade, then co-led the integration project, successfully combining the two companies. In addition, Mr. Dennison serves as Chairman of the Board of CareVet Holdings and as a Board Member of FinTech Studios.

About Arch Oncology

Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. The Company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. Arch Oncology’s lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, the Company is advancing a number of pipeline programs, including anti-signal regulatory protein (SIRP) antibodies. Arch Oncology’s leadership team has successfully developed new drugs for patients before and is backed by leading investors, including RiverVest Venture Partners, Roche Venture Fund, 3×5 RiverVest Partners II-B, and Lightchain. For more information please visit www.archoncology.com.

Media Contact:
Amy Figueroa
For Arch Oncology
afigueroa@archoncology.com

View all news

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.4.8″ background_color=”#0097ca” custom_margin=”0px||0px|” custom_padding=”0||0||true|false” top_divider_style=”curve2″ top_divider_color=”#ffffff” top_divider_flip=”vertical” da_disable_devices=”off|off|off” disabled=”on” global_module=”6648″ saved_tabs=”all” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”3.25″ background_color=”#0191ac” max_width=”1080px” custom_padding=”0|0px|0|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ background_color=”#0191ac” custom_padding=”|||” custom_padding__hover=”|||”][/et_pb_column][/et_pb_row][/et_pb_section]